Safe and Cheap Stocks for Cautious Investors
These companies have below-average risk and reasonable valuations.
These companies have below-average risk and reasonable valuations.
With the market's sporadic gains over the past few weeks, riskier fare is once again back in fashion. For the trailing six-month period ending March 20, 2003, Morningstar's speculative-growth category was the best performer of all eight stock types. The computer-hardware sector has also been on a tear, with gains of close to 30% over the past six months.
But after suffering painful losses for the past three years, many stock investors might be reluctant to dive back into the riskiest areas of the market. Fortunately, more-conservative investors can still find some opportunities in shares of stable companies that are still trading at reasonable valuations. Using Morningstar's Premium Stock Screener, we searched our database to narrow down the field.
First, we restricted the search to stocks covered by Morningstar analysts, which limited the group to roughly 1,000 companies. To find companies with a low level of risk, we focused on company fundamentals, as opposed to quantitative measures such as beta. While beta can give you a good idea of how volatile a stock has been in the past, we think company fundamentals are a better gauge of how much risk you're taking on as an investor. Morningstar's stock analysts assign qualitative ratings for business risk for each of the stocks they cover, incorporating factors such as debt leverage, free cash flow, and the sustainability of operating cash flows and growth. We limited our search to companies with business risk ratings of below average, which cut the group down to fewer than 100 names.
Investors are generally willing to pay a premium price for safety, so it's usually tough to find reliable companies that trade at a discount. To make sure that our ideas weren't trading at excessive valuations, we also limited the field to stocks with 4- or 5-star Morningstar ratings. Morningstar's stock ratings are based on the difference between a stock's price and our estimate of its fair value, so stocks trading at a discount are more likely to win a better-than-average rating.
All told, 26 stocks made it through the acid test. Here are some of the highlights:
Federated Investors (FII)
Economic Moat: Narrow
Business Risk: Below Average
From the Analyst Report: "Managing primarily money market funds, Federated is one of the more defensive asset managers. We would be happy to own a piece of this growing business at the right price. We think that the shares are worth $41 and that they are a bargain below $25."
Novartis (NVS)
Economic Moat: Wide
Business Risk: Below Average
From the Analyst Report: "Novartis is a keeper, in our opinion. The Swiss drug giant looks like a European version of Johnson & Johnson (JNJ), with two thirds of its revenue coming from high-margin pharmaceuticals and the other third from health-care staples like vitamins, baby food, and foot fungus treatments. Novartis offers solid revenue growth with a healthy dose of stability, making it one of our favorites in the pharmaceutical industry."
John Wiley & Sons (JW.A)
Economic Moat: Wide
Business Risk: Below Average
From the Analyst Report: "High barriers to entry and high switching costs associated with its business afford John Wiley a wide economic moat. We think the shares are an outstanding investment below $24. In addition to its wide economic moat, we're attracted to Wiley because of its outstanding profits. Returns on invested capital have averaged 15% over the past five years, among the highest in the industry."
Sysco (SYY)
Economic Moat: Wide
Business Risk: Below Average
From the Analyst Report: "Though it may not have the name recognition of McDonald's (MCD) or Coca-Cola (KO), Sysco has built a formidable and profitable business as a middleman between manufacturers and the food-service industry. With $23 billion in annual sales and more than 400,000 customers spread across the United States and Canada, Sysco boasts economies of scale unparalleled in this highly fragmented field."
To run this screen yourself and see all the stocks that meet our criteria, click here. After clicking, you can save the screening criteria by using the "Save Criteria" button in the bottom right-hand corner of the screen.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.